Scholarlink

Background <p>Pancreatic cystic lesions (PCLs) have variable malignant potential, and distinguishing benign from malignant/premalignant cysts is challenging for optimal management. Trans-abdominal ultrasound (TAUS), a widely available, non-invasive, low-cost first-line pancreatic imaging tool, is underexplored for predicting PCL malignant potential. This study aimed to develop a TAUS feature-based nomogram for this purpose.</p> Methods <p>This retrospective study included 161 patients with pathology-confirmed PCLs from December 2012 to July 2021, divided into benign (59 cases) and non-benign (premalignant/malignant, 102 cases) groups. Relevant clinical characteristics and TAUS features were collected. Least absolute shrinkage and selection operator (LASSO) logistic regression analysis was used to optimize feature selection. Multivariate logistic regression analysis was applied to construct the nomogram. The performance of the nomogram was assessed via receiver operating characteristic curves, calibration curves and decision curve analysis (DCA).</p> Results <p>Among the 26 features collected, 11 features were chosen via LASSO analysis. Multivariate analysis identified echogenicity, the configuration of cysts, solid content and septation/wall thickening as independent predictors. The prediction nomogram model developed with these four variables showed moderate discriminative performance in differentiating non-benign from benign PCLs, with an area under the curve (AUC) of 0.781. Regarding internal verification, tenfold cross-validation yielded a C-index of 0.749. The Hosmer–Lemeshow test yielded a <i>P</i> = 0.945, suggesting that the model had a good fit. Additionally, DCA demonstrated good net clinical benefit.</p> Conclusions <p>This study explored the value of TAUS features for predicting the malignant potential of PCLs. The incorporation of TAUS features into a nomogram may offer a potential non-invasive tool to help clinicians in risk stratification during the initial evaluation and follow-up assessment of PCLs patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A nomogram for malignancy prediction of pancreatic cystic lesions based on trans-abdominal ultrasound features

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Liyuan Ma,
  • Ya Hu,
  • Yu Xia,
  • Jiang Ji,
  • Jionghui Gu,
  • Nengwen Luo,
  • Aonan Pan,
  • Yang Cao,
  • Yuang An,
  • Luying Gao,
  • Yuxin Jiang

摘要

Background

Pancreatic cystic lesions (PCLs) have variable malignant potential, and distinguishing benign from malignant/premalignant cysts is challenging for optimal management. Trans-abdominal ultrasound (TAUS), a widely available, non-invasive, low-cost first-line pancreatic imaging tool, is underexplored for predicting PCL malignant potential. This study aimed to develop a TAUS feature-based nomogram for this purpose.

Methods

This retrospective study included 161 patients with pathology-confirmed PCLs from December 2012 to July 2021, divided into benign (59 cases) and non-benign (premalignant/malignant, 102 cases) groups. Relevant clinical characteristics and TAUS features were collected. Least absolute shrinkage and selection operator (LASSO) logistic regression analysis was used to optimize feature selection. Multivariate logistic regression analysis was applied to construct the nomogram. The performance of the nomogram was assessed via receiver operating characteristic curves, calibration curves and decision curve analysis (DCA).

Results

Among the 26 features collected, 11 features were chosen via LASSO analysis. Multivariate analysis identified echogenicity, the configuration of cysts, solid content and septation/wall thickening as independent predictors. The prediction nomogram model developed with these four variables showed moderate discriminative performance in differentiating non-benign from benign PCLs, with an area under the curve (AUC) of 0.781. Regarding internal verification, tenfold cross-validation yielded a C-index of 0.749. The Hosmer–Lemeshow test yielded a P = 0.945, suggesting that the model had a good fit. Additionally, DCA demonstrated good net clinical benefit.

Conclusions

This study explored the value of TAUS features for predicting the malignant potential of PCLs. The incorporation of TAUS features into a nomogram may offer a potential non-invasive tool to help clinicians in risk stratification during the initial evaluation and follow-up assessment of PCLs patients.